Dr. Benjamin Renquist, PhD
Dr. Benjamin Renquist is the inventor of the technology that is the backbone of GenetiRate. As Founder and Chief Scientific Officer, Dr. Renquist leads GenetiRate research and development. Dr. Renquist has BS (Colorado State University) and MS (UC Davis) training in Animal Science and a PhD (UC Davis) in nutrition. He did post-doctoral training with National Academy member Roger Cone at Oregon Health and Science University and Vanderbilt University Medical Center. In 2007, Dr. Renquist began research in zebrafish and upon moving to the University of Arizona began a research program in Tilapia. He has additionally conducted research in pacific oysters, trout, and shrimp. Dr. Renquist has led his independent research laboratory at the University of Arizona since 2011 and has learned through19 years of metabolism research and 12 years of fish research.
Kyle Kentch, M.S.
Director of Technical Development
Kyle, a co-owner, led the research conducted in Dr. Renquist's University of Arizona laboratory to validate the application of this test in aquacultural species. Kyle trained at the University of Rochester (BS) and Cornell Univeristy (MEng). He applied his Masters in biomedical engineering to lead the design and development of our automated sorter that allows for the GenetiRate assay to be applied at scale.
Jason Cleaversmith, PhD
Director of Business Development
Jason Cleaversmith has a breadth of experience in the environmental, aquaculture and life sciences, having operated at both the interface of, and within the commercial, economic development and technology transfer sectors. He is a graduate of Edinburgh University, Scotland, majoring in natural sciences followed by a PhD in Marine Geochemistry and has subsequently completed an Executive MBA with the University of Glasgow, where he gained a Distinction.
Prior to joining GenetiRate, Jason worked with AKVA Group Scotland, the Scottish Aquaculture Innovation Centre (SAIC), and as the Head of the Novartis Aqua Health presence on Prince Edward Island, Canada where he oversaw 4 facilities, 125 staff and both R&D and Manufacturing related activities. Before joining Novartis, Dr. Cleaversmith led the Bioscience portfolio on behalf of the Province of Prince Edward Island and was responsible for the growth and economic development of the cluster by way of both inward investment and existing company growth.
His career spans time in Blue Chip organizations through to frontline SME positions in roles such as Business Development Director and Head of Operations. In addition, he was a member of the Executive at the Scottish Association for Marine Science and led from inception the development of their commercial subsidiary and technology / knowledge transfer activities, including the building and population of the European Centre for Marine Biotechnology.
He is a Fellow of the Royal Society of Biology, Chartered Manager and is a member of the Institute of Directors. Prior voluntary positions include chair of the board for the University of Prince Edward Islands technology transfer office (Synapse), Vice Chair of the PEI BioAlliance and membership of the KTN animal health advisory board.